Trial Title:
Combination Therapy for Recurrent Ovarian Cancer
NCT ID:
NCT05610735
Condition:
Recurrent Ovarian Cancer
Conditions: Official terms:
Ovarian Neoplasms
Carcinoma, Ovarian Epithelial
Recurrence
Doxorubicin
Liposomal doxorubicin
Conditions: Keywords:
DOXIL
Withaferin A
Ashwagandha
Recurrent Ovarian Cancer
Combination therapy
Study type:
Interventional
Study phase:
Phase 1/Phase 2
Overall status:
Recruiting
Study design:
Allocation:
N/A
Intervention model:
Single Group Assignment
Intervention model description:
Recurrent Ovarian Cancer Participants treated with combination of DOXIL and Ashwagandha
Primary purpose:
Treatment
Masking:
None (Open Label)
Intervention:
Intervention type:
Drug
Intervention name:
DOXIL
Description:
DOXIL will be administered IV as 40 mg/m2 IV every four weeks for 4 cycles or until
disease progression and/or unacceptable toxicity, whichever comes first to a maximum of
10 cycles.
Arm group label:
Combination of DOXIL and Ashwagandha
Other name:
Liposomal doxorubicin
Intervention type:
Drug
Intervention name:
Withaferin A
Description:
Ashwagandha in the form of tablets will be administered orally on daily basis.
Arm group label:
Combination of DOXIL and Ashwagandha
Other name:
Ashwagandha
Intervention type:
Drug
Intervention name:
Ashwagandha
Description:
Administered orally on daily basis twice a day
Arm group label:
Combination of DOXIL and Ashwagandha
Other name:
ASWD
Intervention type:
Drug
Intervention name:
Combination of ASWD and DOXIL
Description:
DOXIL administered IV once every four weeks. ASWD administered orally on daily basis,
twice a day.
Arm group label:
Combination of DOXIL and Ashwagandha
Other name:
ASWD and DOXIL
Summary:
The proposed study "combination therapy with liposomal doxorubicin and withaferin A
(Ashwagandha, ASWD) in recurrent ovarian cancer" is focused to determine the feasibility
and maximum tolerance dose of Ashwagandha with liposomal doxorubicin (DOXIL) in recurrent
ovarian cancer patients. The study contains two parts. In part 1 (phase I), 18 patients
with recurrent ovarian cancer eligible for DOXIL therapy will be recruited and three
doses of Ashwagandha (2.0 g, 4.0 g and 8.0 g) in the form of tablets along with DOXIL
will be evaluated for feasibility and tolerance of ASWD. In part 2 (phase II), 54
patients with recurrent ovarian cancer will be recruited and treated with DOXIL and
Ashwagandha (dose determined from part 1) to evaluate the complete response (CR), partial
response (PR), and stable disease (SD).
Detailed description:
Study Design Overview:
This is a two-part open-label clinical trial of ASWD (Ashwagandha) administered to
patients with recurrent ovarian cancer in combination with liposomal doxorubicin, (DOXIL)
following at least one previous line of chemotherapy. Patients will initially be enrolled
in part 1 of the study, which is the feasibility/tolerability evaluation. Once the part 1
enrollment is completed, the patients will be enrolled in part 2 of the study.
In both parts, ASWD will be administered orally daily whereas liposomal doxorubicin will
be administered intravenously (IV) every 4 weeks for at least 4 cycles or until disease
progression and/or unacceptable toxicity, whichever comes first. If disease progression
and/or unacceptable toxicity is not encountered, study treatment will be for a maximum of
10 cycles, or until a total cumulative dose of anthracycline therapy exceeds 450 mg/m2.
Continued treatment with liposomal doxorubicin and/or ASWD will be determined by the
provider. Once there is a completion of 10 cycles, ASWD will be continued in a daily
regimen as maintenance, without continued liposomal doxorubicin, until disease
progression and/or unacceptable toxicity.
Part 1 Part 1 (Phase I) is a feasibility/tolerability evaluation in which approximately
18 patients with recurrent ovarian cancer will be enrolled. The enrolled patients will be
treated with 3 doses of ASWD [1.0 g, 2.0 g or 4.0 g/twice daily (total 2.0 g, 4.0 g or
8.0 g/day) taken orally with water in the form of capsule (500 mg/capsule, containing 500
mg of active ashwagandha)] in combination with set dosage of DOXIL (40 mg/m2 over 60 min,
every 4 weeks). DOXIL will be administered at an initial rate of 1 mg/min to minimize the
risk of infusion reactions. If no infusion related reactions occur, infusion rate will be
increased to complete administration over 1 hour. Bolus injection or undiluted solution
will not be administered.
Dose Escalation:
Approximately 18 subjects will be enrolled to escalating dose levels of ASWD in
combination with DOXIL the approved dose of 40 mg/m2. Each dose level will initially
enroll at least 3 DLT-evaluable subjects to a maximum of 6 subjects. Subsequent subjects,
if any, assigned to receive the same dose level will be enrolled in groups of at least 2
DLT-evaluable subjects. Table 1 provides the dose escalation decision with target
toxicity rate of 28.5% and optimal interval of (25.6%, 32.7%).
The ASWD starting dose level is 2.0 g, administered daily orally, starting with Cycle 1.
The DOXIL dose level is fixed dose of 40 mg/m2 IV for every 4 weeks. The escalation dose
of ASWD will be 4.0 g/day or 8.0 g/day for second and third cohort respectively and fixed
dose of DOXIL. ASWD will be given alone if patient is no longer receiving DOXIL
treatments. However, it will be given along with DOXIL if the patient continues DOXIL
after 4 cycles.
The DLT observation period consists of the lead-in period [7 days of ashwagandha and
Cycle 1 (21 days)] for 28 days total. To be considered DLT evaluate, subjects must
complete at least 75% of ASWD dosing (i.e., at least 21 days) in the lead-in period and
Cycle 1 or experience a DLT. DLT non-evaluate subjects may be replaced if needed to
achieve the required number of DLT-evaluable subjects for dose escalation decisions.
Dose-limiting toxicities will be graded using the Common Terminology Criteria for Adverse
Events (CTCAE) Version 5.0 (CTCAE v5.0).
https://ctep.cancer.gov/protocoldevelopment/electronic_applications/docs/ctcae_v5_quick_r
eference_5x7.pdf.
Ashwagandha is sold as an over-the-counter dietary supplement rich in WFA in 500 mg
tablets containing 500 mg of active ashwagandha. ASWD will be provided by Marudhar Impex,
Ahmedabad, India. Ashwagandha is manufactured and packed to capsules by Marudhar Impex
under cGMP and analyzed by Eurofins Analytical Services India Private Limited. ASWD is
extracted from the plant Withania somnifera grown under control conditions and packed in
a Good Manufacturing Practices (GMPs) facility. It contains 0.71 % (w/w) Withanoside IV,
01.14% Withaferin A, 0.27% Withanoside V, 0.33% Withanone, 0.09% withanolide A, and 0.00%
withanolide B determined by HPLC. The investigators will confirm the content of
withaferin A using HPLC.
DOXIL is a liposomal formulation of doxorubicin hydrochloride encapsulated in liposomes
with surface-bound methoxypolyethylene glycol (MPEG). Each liposomal doxorubicin vial
contains pegylated liposomal doxorubicin HCl, 2 mg/mL and delivered as 10 ml (20 mg) in a
concentrate for single dose intravenous infusion and is presented as sterile,
translucent, and red suspension. For < 90 mg/m2, DOXIL is diluted in 250 ml Dextrose 5%
in water and for > 90 mg/m2 DOXIL is diluted in 500 mL Dextrose in 5% in water. Aseptic
technique must be strictly observed since no preservative or bacteriostatic agent is
present in DOXIL. Diluted DOXIL should be refrigerated at 2°C to 8°C (36°F to 46°F) and
administered within 24 hours.
Part 1 (Phase I) Part 1 of the study will be conducted using '3 + 3' traditional dose
escalation design. Toxicities will be graded using the NCI Common Terminology Criteria
for Adverse Events (CTCAE) Version 5.0 (CTCAE v5.0). Initially, 3 patients will be
treated with 1.0 gram of ASWD twice daily (total of 2.0 grams/day) in combination with
DOXIL, if none of them develop toxicity, then next 3 patients will be treated with 2.0
grams twice (total 4.0 grams/day) in combination with DOXIL, if none of them develop
toxicity or has any issue, then next 3 patients will be treated with 4.0 grams twice
daily (total 8.0 grams/day) in combination with DOXIL. If any of the patients has a Grade
3-4 hematologic or non-hematologic toxicity, the cohort will be expanded by three
subjects (with a maximum of 6 patients at a given dose), prior to proceeding to the next
dose. DOXIL dose will be 40 mg/m2 administered IV over a period of 60 min every 4 weeks
for 4 cycles or until disease progression and/or unacceptable toxicity, whichever comes
first to a maximum of 10 cycles. The total anthracycline (doxorubicin) cumulative dose
should not exceed over 450 mg/m2.
AWSD will be administered on days 1-28 of each cycle. Patients will start ASWD on cycle
1, day 1 of DOXIL infusion. ASWD administration instructions will be provided to
participants as follows:
"Take (appropriate number of capsules per dose escalation) tablets every 12 hours; to be
initiated the day of starting chemotherapy." The medication may be taken with or without
water and with or without food. If a dose is missed, it will not be re-taken.
Participants will be instructed to keep a dose log. AWSD may be stored at ambient
temperature protected from light at the participants' home. Plasma and urine samples will
be collected for analysis of selected circulating biomarkers (proteins).
Part 2 (Phase II) Part 2 is an open label, exploration study to estimate the overall
survival and response rate for participants treated daily with ASWD in the form of
tablets in combination with DOXIL (40 mg/m2 IV for every 4 weeks for 4 cycles).
Approximately 54 patients (including part 1 subjects treated with the highest feasible
dose) will be enrolled in part 2 of the study. The enrollment for part 2 of the study
will begin with the ASWD and liposomal doxorubicin dosages determined from part 1,
provided no more than 2 out of 6 patients develop treatment related non-hematological
toxicity in part 1 of the study. The enrolled patients will start taking ASWD capsules
identified in part 1 for evaluation in part 2. Patients who participated in part 1 of the
study will be offered to continue treatment to part 2, with a maximum tolerable dose.
DOXIL will be administered every 4 weeks (40 mg/m2) for up to 10 cycles (limited to the
standard limit of anthracycline administration, 450 mg/m2 cumulative dose of doxorubicin
HCL). In the event of no progression and tolerance of the drug, patients should continue
ASWD even DOXIL is stopped.
Dose Limiting Toxicities (DLT) The dose limiting toxicity window will include the first
cycle of therapy (four weeks) and will be monitored prior to the initiation of cycle 2.
Laboratory values will be measured weekly during cycle one of therapy, then prior to each
administration of DOXIL. These will include complete blood count (CBC) with platelets and
complete metabolic panel (CMP) with liver function tests. In addition, prothrombin time
and partial thromboplastin time will be monitored, simultaneously.
Hepatic Toxicity: Grade 3-4 hepatic toxicity will be defined as AST or ALT >3X upper
limits of normal (ULN) and a concurrent bilirubin >2X ULN of any duration without finding
of cholestasis (elevated alkaline phosphatase).
Hematologic Toxicity: Hematologic toxicity will be defined as: 1) Grade 4 neutropenia or
thrombocytopenia > 7 days; 2) Grade 3 thrombocytopenia with bleeding; and 3) neutropenia
fever.
Non-Hematologic Toxicity: Non-Hematologic toxicity will be defined as 1) Grade 4
alopecia, drug-related fever, and toxicities secondary to neutropenia and sepsis [with
the exception of nausea and vomiting (if manageable with supportive care measures)],
platelet count (< 25,000/mm3) 50 days beyond the start of the chemotherapy (not related
to recurrent leukemia); 2) Grade 3 neurologic toxicity (sensory or autonomic).
Grade 3-4 non-hematologic toxicities will be considered a DLT and can be exempted from
DLT if they resolve within 1 week, if they do not lead to hospitalization, and if they
can be adequately managed with supportive care or conventional interventions within 72
hours.
Death: Any death not clearly due to underlying disease or extraneous causes
Criteria for eligibility:
Criteria:
Inclusion Criteria:
Patients with recurrent ovarian/fallopian tube/primary peritoneal cancer for whom
liposomal Doxorubicin would be an acceptable therapeutic option will be recruited.
Patients are eligible if they have received first line chemotherapy containing platinum
and have become platinum resistance or have refractory disease. The patient must also
meet all the following criteria:
1. Signed approved informed consent document stating that they understand the
investigational nature of the treatment program before entering study
2. Female patients, age ≥ 18 years
3. Pathological confirmed ovarian, fallopian tube, or primary peritoneal carcinoma with
the one of the following histologic types: high grade papillary serous carcinoma,
low grade papillary serous carcinoma, high grade mucinous carcinoma, low grade
mucinous carcinoma, clear cell carcinoma, high grade endometrioid carcinoma.
4. Received at least one line chemotherapy, which must be a platinum containing regimen
and develop platinum resistance. Patients may have not received previous liposomal
doxorubicin therapy, and must be considered to be eligible for single agent
liposomal doxorubicin treatment.
5. Patients may have undergone surgical cytoreduction at the time of primary diagnosis
or following neoadjuvant chemotherapy. Patients who had optimal (<1 cm residual
disease) or suboptimal (>1 cm residual disease) following surgical cytoreduction
will be included.
Patients who did not undergo surgical cytoreduction will also be included.
6. Recurrent disease confirmed by biopsy, radiologic imaging, and/or elevated CA 125
7. Patients may have received radiation therapy
8. Life expectancy > 6 months
9. Part 1: Have evaluable disease by radiologic measurements (See 11) or CA 125
10. Part 2: Have measurable disease, defined as at least 1 lesion that can be accurately
measured in at least 1 dimension (longest diameter to be recorded) as > 1 cm on
cross-sectional imaging (where the CT slice thickness is no greater than 5 mm) or at
least 2 cm by standard techniques; positron emissions tomography (PET] and
ultrasound are not permitted methods for tumor measurements under this protocol.
Consult RECIST 1.1 guidance for additional information (Appendix C and Eisenhauer et
al., 2009; Ref 61).
11. Adequate organ function within 14 days prior to first WFA/ASWD dose or liposomal
doxorubicin whichever occurs first, including the following: absolute neutrophil
count (ANC) ≥ 1.5 x 103/L, platelet count ≥ 100 x 103/L, hemoglobin ≥ 9 g/dL (≥ 5.6
mmol/L), patients may receive packed RBC transfusion to achieve this level at the
discretion of the investigator, total bilirubin < 1.5 x upper limit of normal (ULN)
unless elevated secondary to conditions such as Gilbert's Disease, aspartate
aminotransferase (AST) < 3 x ULN (< 5 x ULN in the presence of hepatic metastases),
alanine aminotransferase (ALT) < 3 x ULN (< 5 x ULN in the presence of hepatic
metastases), alkaline phosphatase < 3.0 x ULN, calculated creatinine clearance ≥ 60
mL/min per Cockcroft and Gault formula
12. Satisfy one of the following:
- Females: non-pregnant and non-lactating; surgically sterile, post- menopausal,
or patient/partner compliant with a reliable contraceptive regimen, as
determined by the investigator, for 4 weeks prior to screening.
- Patients of reproductive potential must test negative for pregnancy at
screening, prior to each cycle, and must agree to use a reliable method of
birth control during the study period and 6 months following completion of
treatment.
13. The patient is willing and able to comply with the study visit schedule and
procedures and has geographical proximity (Investigator's discretion) that allows
follow-up specified by the protocol
14. For Part 1: Patients have discontinued all prior chemotherapies, biological
therapies, and other investigational therapies for cancer for at least 4 weeks prior
to study treatment and have recovered from the acute effects of therapy
15. ECOG performance status of 0, 1, or 2
16. Adequate ejection fraction determined by transthoracic echo or MUGA of at least 55%
17. Patients may have received prior anthracycline or anthracenedione therapy. In this
scenario, the use of prior treatments will be incorporated into the cumulative dose
calculations when applicable, given a known increased risk of cardiomyopathy to 11%
when the cumulative dose of liposomal doxorubicin was between 450 mg/m2 to 550
mg/m2.
- Exclusion Criteria:
Patients will be excluded from the study if they meet any of the following criteria:
1. ECOG performance status 3 or 4
2. Pregnant or breastfeeding
3. Treatment with another investigational drug, biological agent, or device within 4
weeks (6 weeks for biological agents) before screening or 5 half-lives of study
agent, whichever is longer
4. Patients with treated or untreated parenchymal brain metastases or leptomeningeal
disease. Brain imaging is required for symptomatic patients to rule out brain
metastases, but is not required in asymptomatic patients
5. Patients with known pericardial effusion
6. Patients with active infection or serious concomitant systemic disorder (for
example, heart failure) incompatible with the study (at the discretion of the
Investigator)
7. Presence or history of malignancy other than ovarian cancer that does not include
carcinoma in situ of the cervix, or non-melanoma skin cancer. In the case of other
malignancies, patients may be considered for participation if the prior malignancies
were diagnosed and definitively treated at least two years previously with no
subsequent evidence of recurrence
8. Presence of an underlying disease state associated with active bleeding
9. Concurrent treatment with other anticancer drugs
10. Planned concomitant participation in another clinical trial of an experimental
agent, vaccine, or device
11. Patients with any other medical conditions that, in the opinion of the Investigator,
would make the patient unsuitable for enrollment, or could interfere with the
patient participating in or completing the study
12. Patients with known septicemia, severe infection, or acute hepatitis
13. Patients with known congestive heart failure or unstable angina or those who had a
myocardial infarction within the past 6 months
14. Patients with known clinically significant pericardial disease
15. Patients taking medications known to affect the cardiac conduction system
16. Allergy to WFA/ASWD
17. Previous treatment with liposomal doxorubicin
18. Prior use of other anthracyclines or anthracenediones -
Gender:
Female
Gender based:
Yes
Gender description:
Pathological confirmed ovarian, fallopian tube, or primary peritoneal carcinoma with the
one of the following histologic types: high grade papillary serous carcinoma, low grade
papillary serous carcinoma, high grade mucinous carcinoma, low grade mucinous carcinoma,
clear cell carcinoma, high grade endometrioid carcinoma, undifferentiated carcinoma,
mixed epithelial carcinoma, and adenocarcinomas not otherwise specified
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
UofL Health Brown Cancer Center
Address:
City:
Louisville
Zip:
40202
Country:
United States
Status:
Recruiting
Contact:
Last name:
Whitney Goldsberry, MD
Phone:
502-562-4370
Email:
Whitney.Goldsberry@uoflhealth.org
Contact backup:
Last name:
Sham Kakar, PhD, MBA
Phone:
502-852-0812
Email:
sham.kakar@louisville.edu
Investigator:
Last name:
Whitney Goldsberry, MD
Email:
Principal Investigator
Investigator:
Last name:
Sarah Todd, MD
Email:
Sub-Investigator
Start date:
May 2024
Completion date:
November 2027
Lead sponsor:
Agency:
Sham Sunder Kakar
Agency class:
Other
Collaborator:
Agency:
University of Louisville Health Care
Agency class:
Other
Source:
University of Louisville
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05610735
